A study published in BMCMedicine finds that use of anti-malarial drugs proguanil and atovaquone is associated with a decreased risk of colorectal cancer (CRC) among people with a family history of CRC.
]. Clinically, proguanil is usually used in combination with another anti-malarial medicine to increase its effectiveness. In Sweden, a fixed-dose combination proguanil/atovaquone is commonly prescribed to achieve better prevention effects against drug-resistant malaria strains.
For each proguanil/atovaquone user, up to 10 comparisons who did not receive a prescription of proguanil/atovaquone and had not experienced CRC on the date of the first prescription of the corresponding individual were randomly selected based on sex and age at index . In Sweden, proguanil/atovaquone was prescribed for three consecutive days when it was used to treat malaria.
Participants were followed from the date of the first dispensation of proguanil/atovaquone or the index date in the corresponding comparisons and ended at the first date of CRC diagnosis, the date of death from any cause, and the end of this study whichever came first. To minimize reverse causation, patients with a follow-up time of fewer than 3 months were not included in the study.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
BMC launches new Roadmachine 01 AMP X all-road e-bike with 'revolutionary' TQ drive unitFull mudguard mounts, 38mm of tyre clearance, a 2in display and the all new TQ drive unit... would this bike tempt you to switch to electric?
Consulte Mais informação »
BMC Roadmachine AMP X e-road bike gets silent, high-speed TQ motorsSmooth, quiet power delivery and a streamlined look makes the BMC Roadmachine AMP X a stealthy e-road bike under 30 pounds.
Consulte Mais informação »
Inequalities in the impact of COVID-19-associated disruptions on tuberculosis diagnosis by age and sex in 45 high TB burden countries - BMC MedicineBackground Tuberculosis remains a major public health priority and is the second leading cause of mortality from infectious disease worldwide. TB case detection rates are unacceptably low for men, the elderly and children. Disruptions in TB services due to the COVID-19 pandemic may have exacerbated these and other inequalities. Methods We modelled trends in age- and sex- disaggregated case notifications for all forms of new and relapse TB reported to the World Health Organization for 45 high TB, TB/HIV and MDR-TB burden countries from 2013 to 2019. We compared trend predicted notifications to observed notifications in 2020 to estimate the number of people with TB likely to have missed or delayed diagnosis. We estimated the risk ratio (RR) of missed or delayed TB diagnosis for children (aged | 15 years) or the elderly (aged ≥ 65 years) compared to adults (aged 15–64 years) and women compared to men (both aged ≥ 15 years) using a random-effects meta-analysis. Results An estimated 195,449 children (95% confidence interval, CI: 189,673–201,562, 37.8% of an expected 517,168), 1,126,133 adults (CI: 1,107,146–1,145,704, 21.8% of an expected 5,170,592) and 235,402 elderly (CI: 228,108–243,202, 28.5% of an expected 826,563) had a missed or delayed TB diagnosis in 2020. This included 511,546 women (CI: 499,623–523,869, 22.7%, of an expected 2,250,097) and 863,916 men (CI: 847,591–880,515, 23.0% of an expected 3,763,363). There was no evidence globally that the risk of having TB diagnosis missed or delayed was different for children and adults (RR: 1.09, CI: 0.41–2.91), the elderly and adults (RR: 1.40, CI: 0.62–3.16) or men and women (RR: 0.59, CI: 0.25–1.42). However, there was evidence of disparities in risk by age and/or sex in some WHO regions and in most countries. Conclusions There is no evidence at an aggregate global level of any difference by age or sex in the risk of disruption to TB diagnosis as a result of the COVID-19 pandemic. However, in many countries, disrupt
Consulte Mais informação »
Medicine and Mortality in Mali: one health heroine's work to improve community healthMedicine and Mortality in Mali: one health heroine's work to improve community health 🌍 MusoHealth womeninGH interview healthcare community MaternalHealth
Consulte Mais informação »
NI Protocol: Medicine supply still faces 'significant issue'Pharmaceutical firm tevapharmeurope said there are unresolved issues around medicine supplies and the protocol 💊 Brexit
Consulte Mais informação »
Fulminant Myocarditis with Combination Immune Checkpoint Blockade | NEJMOriginal Article from The New England Journal of Medicine — Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Consulte Mais informação »